Status:
COMPLETED
FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of Lymphoma
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
FDG-PET/CT is an established modality in various stages of management of lymphoma but definitive information regarding the diagnosis, prognostication, and further management is provided by histopathol...
Detailed Description
Written informed consent was obtained from all the participants for PET/CT-guided biopsy. The procedure details, related risks, and benefits were explained to all the participants. A multidisciplinary...
Eligibility Criteria
Inclusion
- FDG avid lesion in a clinically suspected case of lymphoma.
- Suspicious, residual FDG avid lesion detected at the time of follow-up PET/CT imaging in a patient with a prior diagnosis of lymphoma either at the end-of-treatment or during surveillance.
Exclusion
- Deranged coagulation profile.
- Inaccessibility of the lesion for a percutaneous biopsy.
- Resolution of the lesion at the time of biopsy planning.
- Participant is not willing for the procedure.
- Pregnant females and participants less than 18 years of age.
Key Trial Info
Start Date :
October 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2022
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT05186610
Start Date
October 1 2017
End Date
August 31 2022
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, PGIMER
Chandigarh, Chandigarh, India, 160012